Effects of oseltamivir phosphate (Tamiflu) and its metabolite (GS4071) on monoamine neurotransmission in the rat brain

Biological and Pharmaceutical Bulletin

Volumn 30, Issue 9, 2007, Pages 1816-1818

  Satoh, Kanako ^a   Nonaka, Ryouichi ^a   Ogata, Akio ^a   Nakae, Dai ^a   Uehara, Shin Ichi ^a  

^a TOKYO METROPOLITAN INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

Dopamine; GS4071; Norepinephrine; Oseltamivir phosphate; Serotonin; Tamiflu

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; BRAIN MONOAMINE; DOPAMINE; DRUG METABOLITE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); NEUROTRANSMITTER; NORADRENALIN; OSELTAMIVIR; SEROTONIN;

ABNORMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BRAIN; CENTRAL NERVOUS SYSTEM; DOPAMINE RELEASE; DOPAMINE UPTAKE; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; MALE; MONOAMINE RELEASE; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENALIN RELEASE; NORADRENALIN UPTAKE; PRESYNAPTIC NERVE; RAT; SEROTONIN RELEASE; SEROTONIN UPTAKE; SPRAGUE DAWLEY RAT; SYNAPTOSOME;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIVIRAL AGENTS; BIOGENIC MONOAMINES; BRAIN CHEMISTRY; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); GUANOSINE TRIPHOSPHATE; MALE; NOREPINEPHRINE; OSELTAMIVIR; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SYNAPTIC TRANSMISSION; SYNAPTOSOMES;

EID: 34548611356     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.30.1816     Document Type: Article

References (19)

1. Eisenberg E. J., Bidgood A., Cundy K. C., Antimicrob. Agents Chemother., 41, 1949-1952 (1997).
2. http://www.mhlw.go.jp/shingi/2007/05/s0502-1.html/B%27&extension= html&search_lang=japanese
3. http://www.mhlw.go.jp/houdou/2007/04/h0425-1.html
4. Morishima T., Nippon Rinsho, 61, 2006-2012 (2003).
5. http://www.city.shinjuku.tokyo.jp/division/340700yobo/infuruenza.htm#_top
6. Kido H., Yao D., Le T. Q., Tsukane M., Chida J., Nippon Rinsho, 64, 1879-1886 (2006).
7. Dutkowski R., Thakrar B., Froehlich E., Suter P., Oo C., Ward P. Drug Saf., 26, 787-801 (2003).
8. Okamoto S., Kamiya I., Kishida K., Shimakawa T., Fukui T., Morimoto T., Pediatr. Inf. Disease J., 24, 575-576 (2005).
9. http://www.mhlw.go.jp/topics/2006/10/dl/tp1020-2.pdf
10. Nagai F., Nonaka R., Satoh K., Kamimura H., Eur. J. Pharmacol., 559, 132-137 (2007)
11. http://www.fda.gov/medwatch/SAFETY/2003/tamiflu_deardoc.pdf
12. Fukuta Y., Mita T., Fukuda N., Kanai M., Shibasaki M., J. Am. Chem. Soc., 128, 6312-6313 (2006).
13. Mita T., Fukuda N., Roca F. X., Kanai M., Shibasaki M., Org. Lett., 9, 259-262 (2007).
14. Satoh K., Nonaka R., Tada Y., Fukumori N., Ogata A., Yamada A., Satoh T., Nagai F., Arch. Toxicol., 80, 605-613 (2006).
15. Breivogel C. S., Walker J. M., Huang S. M., Roy M. B., Childers S. R., Neuropharmacology, 47, 81-91 (2004).
16. Moore R. J., Xiao R., Sim-Selley L. J., Childers S. R., Neuropharmacology, 39, 282-289 (2000).
17. Bhat N., Wright J. G., Broder K. R., Murray E. L., Greenberg M. E., Glover M. J., Likos A. M., Posey D. L., Klimov A., Lindstrom S. E., Balish A., Medina M. J., Wallis T. R., Guarner J., Paddock C. D., Shieh W. J., Zaki S. R., Sejvar J. J., Shay D. K., Harper S. A., Cox N. J., Fukuda K., Uyeki T. M., N. Engl. J. Med., 353, 2559-2567 (2005).
18. Nordstrom B. L., Sung I., Suter P., Szneke P., Curr. Med. Res. Opin., 21, 761-768 (2005).
19. Sugaya N., Influenza, 8, 31-34 (2007).